TY - JOUR
T1 - GLP-1 receptor agonist and non-alcoholic fatty liver disease
AU - Lee, Jinmi
AU - Hong, Seok Woo
AU - Rhee, Eun Jung
AU - Lee, Won Young
PY - 2012/8
Y1 - 2012/8
N2 - Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.
AB - Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.
KW - Fatty acid oxidation
KW - Glucagon-like peptide 1
KW - Non-alcoholic fatty liver disease
UR - https://www.scopus.com/pages/publications/84869011851
U2 - 10.4093/dmj.2012.36.4.262
DO - 10.4093/dmj.2012.36.4.262
M3 - Review article
AN - SCOPUS:84869011851
SN - 2233-6079
VL - 36
SP - 262
EP - 267
JO - Diabetes and Metabolism Journal
JF - Diabetes and Metabolism Journal
IS - 4
ER -
